Ruptured cerebral Aneurysm.
Conditions
Interventions
Intervention 1: Intervention group: Following stent placement, patients in this group will receive cilostazol 100 mg every 12 hours for six months, along with ticagrelor 90 mg every 12 hours for one y
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: All patients with cerebral aneurysm who are above the age of 20 All patients with ruptured cerebral aneurysm
Exclusion criteria
Exclusion criteria: Unruptured aneurysms Coagulopathies (including an International Normalized Ratio (INR) > 1.5 or a platelet count 2.5 mg/dL) High risk of bleeding (e.g., active peptic ulcer or recent gastrointestinal bleeding) Use of cilostazol within the past 6 months Known intolerance to cilostazol or ticagrelor Severe heart failure with an ejection fraction (EF) < 30% A requirement for warfarin therapy Hepatic insufficiency
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Thromboemboli. Timepoint: Beginning at the start of the study and continuing for one year. Method of measurement: Clinical signs and Computed Tomography Angiography. | — |
Primary
| Measure | Time frame |
|---|---|
| The percentage of stenosis developed in the cerebral aneurysm stent. Timepoint: Measurement of stent lumen diameter immediately after deployment and at 6 and 12 months post-deployment. Method of measurement: Magnetic Resonance Angiography. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactBahareh Meschian
Iran University of Medical Sciences
Outcome results
None listed